Anti-clusterin monotherapy for cancer treatment

The present invention provides a method of treating cancer in a subject afflicted with cancer comprising administering to the subject an anti-clusterin oligonucleotide as a monotherapy to treat the cancer. The present invention also provides compositions for treating cancer in a subject afflicted with cancer, comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1). Additionally, the present invention provides pharmaceutical compositions for treating cancer in a subject afflicted with cancer, the composition comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

This application claims the benefit of U.S. Provisional Application No. 61/782,584, filed Mar. 14, 2013, the contents of which is hereby incorporated by reference in its entirety.

Throughout this application, various publications are referenced, including referenced in parenthesis. Full citations for publications referenced in parenthesis may be found listed in alphabetical order at the end of the specification immediately preceding the claims. The disclosures of all referenced publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

REFERENCE TO SEQUENCE LISTING

This application incorporates-by-reference nucleotide and/or amino acid sequences which are present in the file named “140312_2609_85022_Sequence_Listing_ACK.txt,” which is 1 kilobyte in size, and which was created Mar. 11, 2014 in the IBM-PC machine format, having an operating system compatibility with MS-Windows, which is contained in the text file filed Mar. 12, 2014 as part of this application.

BACKGROUND OF THE INVENTION

Clusterin is a secretable cytoprotective protein that is upregulated in response to a number of tumor cell killing interventions, specifically chemotherapy, hormone ablation therapy and radiation therapy.

Custirsen (also known as, TV-1011, OGX-011, and Custirsen sodium) is a second-generation antisense oligonucleotide (ASO) that inhibits clusterin expression. It has a 2″-MOE modification to the four ribonucleotides on both ends of the 21-mer phosphorothioate backbone. This results in an increased target binding affinity, resistance to degradation, and substantially better tissue PK than first-generation ASOs. The second-generation antisense molecules have a greater affinity for RNA targets and therefore greater potency, as demonstrated by the improved antisense potency observed in cell culture systems and in animals. In addition, the 2′-MOE modification results in decreased binding affinity to RNase H, the principal nuclease that cleaves ASO-bound RNA, which results in significantly improved tissue half-life in vivo (Gleave et al., 2002). This produces a longer duration of action, allowing less frequent dosing (Bennett et al., 2010). Finally, 2′-MOE ASOs have been reported to have a better safety profile than unmodified phosphorothioate ASOs (Henry et al., 2000).

Custirsen is designed specifically to bind to a portion of clusterin mRNA, resulting in the inhibition of the production of clusterin protein. The structure of custirsen is available, for example, in U.S. Pat. No. 6,900,187, the contents of which are incorporated herein by reference. A broad range of studies have shown that custirsen potently reduces the expression of clusterin, facilitates apoptosis, and sensitizes cancerous human prostate, breast, ovarian, lung, renal, bladder, and melanoma cells to chemotherapy (Miyake et al. 2005), see also, U.S. Patent Application Publication No. 2008/0119425 A1, the contents of which are incorporated herein by reference. Custirsen is not known to be effective for the treatment of cancer as a monotherapy.

New treatments for cancer are needed.

SUMMARY OF THE INVENTION

The present invention provides a method of treating cancer in a subject afflicted with cancer comprising administering to the subject an anti-clusterin oligonucleotide as a monotherapy to treat the cancer.

The present invention provides a composition for treating cancer in a subject afflicted with cancer, comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1).

The present invention provides a composition for treating cancer in a subject afflicted with cancer, comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

The present invention provides a pharmaceutical composition for treating cancer in a subject afflicted with cancer, the composition comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

Aspects of the present invention relate to the use of a composition comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1) for treatment of cancer in a subject afflicted with cancer.

Aspects of the present invention relate to the use of a composition comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1) for preparation of a medicament for treatment of cancer in a subject afflicted with cancer.

The present invention provides a package for use in the treatment cancer in a subject afflicted with cancer, comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: RPMI-8226 tumor volumes. Custirsen reduces tumor growth in vivo. All treatments stopped at day 52. Error Bars denote Standard Error.

FIG. 2: RPMI-8226 tumor volumes. Custirsen reduces tumor growth in vivo. Error Bars denote Standard Error.

FIG. 3: Effect of Custirsen against PC-3.

 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method of treating cancer in a subject afflicted with cancer comprising administering to the subject an anti-clusterin oligonucleotide as a monotherapy to treat the cancer.

In some embodiments, the anti-clusterin oligonucleotide is administered to the subject periodically.

In some embodiments, the anti-clusterin oligonucleotide comprises nucleotides in the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1).

In some embodiments, the anti-clusterin oligonucleotide is modified to increase its stability in vivo.

In some embodiments, the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

In some embodiments, the patient is afflicted with myeloma.

In some embodiments, the patient is afflicted with prostate cancer.

In some embodiments, the cancer is unresectable, advanced or metastatic cancer.

In some embodiments, the subject is a mammalian subject. In some embodiments, the mammalian subject is a human subject.

In some embodiments, the anti-clusterin oligonucleotide is administered to the subject intravenously in an aqueous solution comprising sodium ions.

In some embodiments, the anti-clusterin oligonucleotide is administered to the subject as 3 separate loading doses within a 5 to 9 day period at the beginning of treatment and then once weekly thereafter.

In some embodiments, the dose of the anti-clusterin oligonucleotide increases over each of the 3 loading doses.

In some embodiments, the first, second, and third loading doses are 320, 480, and 640 mg, respectively.

In some embodiments, 640 mg of the anti-clusterin oligonucleotide is administered to the human subject.

The present invention provides a composition for treating cancer in a subject afflicted with cancer, comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1).

The present invention provides a composition for treating cancer in a subject afflicted with cancer, comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

The present invention provides a pharmaceutical composition for treating cancer in a subject afflicted with cancer, the composition comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

Aspects of the present invention relate to the use of a composition comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1) for treatment of cancer in a subject afflicted with cancer.

Aspects of the present invention relate to the use of a composition comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1) for preparation of a medicament for treatment of cancer in a subject afflicted with cancer.

The present invention provides a package for use in the treatment cancer in a subject afflicted with cancer, comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1).

Anti-clusterin oligonucleotides may be used to treat many malignancies including prostate cancer, bladder cancer, ovarian cancer, renal cancer, melanoma, myeloma, breast cancer, lung cancer including NSCLC, and pancreatic cancer, in embodiments of the invention.

In some embodiments, an anti-clusterin oligonucleotide is administered as a monotherapy for treating myeloma or prostate cancer.

Each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments. Thus, all combinations of the various elements described herein are within the scope of the invention.

It is understood that where a parameter range is provided, all integers within that range, and tenths thereof, are also provided by the invention. For example, “0.2-5 mg/kg/day” is a disclosure of 0.2 mg/kg/day, 0.3 mg/kg/day, 0.4 mg/kg/day, 0.5 mg/kg/day, 0.6 mg/kg/day etc. up to 5.0 mg/kg/day.

TERMS

As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.

As used herein, “about” in the context of a numerical value or range means±10% of the numerical value or range recited or claimed, unless the context requires a more limited range.

As used herein, “monotherapy” means a therapy that is administered to treat a disease, such as a cancer, without any other therapy that is used to treat the disease. A monotherapy for treating a cancer may optionally be combined with another treatment that is used to ameliorate a symptom of the cancer while not being directed against the cancer, but may not be combined with any other therapy directed against the cancer, such as a chemotherapeutic agent, hormone ablation therapy, or radiation therapy. Therefore, administering an anti-clusterin oligonucleotide as a monotherapy means administering the anti-clusterin oligonucleotide without radiation therapy, hormone ablation therapy, or any other chemotherapeutic agent. However, in some embodiments of the invention, agents that are not directed against the cancer, for example pain killers or corticosteroids, may be administered concurrently or simultaneously with the anti-clusterin oligonucleotide monotherapy.

As used herein, “anti-clusterin therapy” is therapy which reduces the expression of clusterin. An anti-clusterin therapy may be an anti-clusterin oligonucleotide.

Antisense oligonucleotides (ASOs) are stretches of single-strand deoxyribonucleic acid (DNA) complementary to messenger ribonucleic acid (mRNA) regions of a target gene. Because cellular ribosomal machinery translates mRNA into proteins, expression of specific proteins can be reduced by blocking or reducing this translation.

As used herein, “anti-clusterin oligonucleotide” refers to an antisense oligonucleotide which reduces clusterin expression, and comprises a nucleotide sequence that is complementary to clusterin-encoding mRNA. An example of an anti-clusterin oligonucleotide is custirsen.

As used herein, “custirsen” refers to an anti-clusterin oligonucleotide having nucleotides in the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19. Custirsen can be in the form of Custirsen Sodium.

As used herein, “a human patient afflicted with” a condition, e.g. cancer, means a human patient who was been affirmatively diagnosed to have the condition.

As used herein, “effective” when referring to an amount of custirsen refers to the quantity of custirsen that is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.

As used herein, “treating” encompasses, e.g., inhibition, regression, or stasis of the progression of cancer. Treating also encompasses the prevention or amelioration of any symptom or symptoms of cancer.

As used herein, “inhibition” of disease progression or disease complication in a subject means preventing or reducing the disease progression and/or a disease complication or symptom in the subject.

Dosage Units

Administration of custirsen can be carried out using the various mechanisms known in the art, including naked administration and administration in pharmaceutically acceptable lipid carriers. For example, lipid carriers for antisense delivery are disclosed in U.S. Pat. Nos. 5,855,911 and 5,417,978, which are incorporated herein by reference. In general, custirsen is administered by intravenous (i.v.), intraperitoneal (i.p.), subcutaneous (s.c.), or oral routes, or direct local tumor injection. In some embodiments, custirsen is administered by i.v. injection.

The amount of anti-clusterin oligonucleotide administered may be from 40 to 640 mg, or from 300 to 640 mg. Administration of custirsen may be once in a seven day period, 3 times a week, or more specifically on days 1, 3 and 5, or 3, 5 and 7 of a seven day period. In some embodiments, administration of the antisense oligonucleotide is less frequent than once in a seven day period. In some embodiments, administration of the antisense oligonucleotide is more frequent than once in a seven day period. Dosages may be calculated by patient weight, and therefore in some embodiments a dose range of about 1-20 mg/kg, or about 2-10 mg/kg, or about 3-7 mg/kg, or about 3-4 mg/kg could be used. This dosage is repeated at intervals as needed. One clinical concept is dosing once per week with 3 loading doses during week one of treatment. In some embodiments, the dose of anti-clusterin oligonucleotide increases over the 3 loading doses. In some embodiments, the first, second, and third loading doses are 320, 480, and 640 mg, respectively. The amount of anti-clusterin oligonucleotide administered is one that has been demonstrated to be effective in human patients to inhibit the expression of clusterin in cancer cells.

A dosage unit may comprise a single compound or mixtures of compounds thereof. A dosage unit can be prepared for oral, injection, or inhalation dosage forms.

In some embodiments, custirsen may be formulated at a concentration of 20 mg/mL as an isotonic, phosphate-buffered saline solution for IV administration. In some embodiments, a formulation of custirsen may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% dextrose. In some embodiments, the formulation of custirsen may comprise 5% dextrose. In some embodiments custirsen may be supplied as a 32 mL solution containing 640 mg custirsen sodium in a single vial, or may be supplied as an 8 mL solution containing 160 mg custirsen sodium in a single vial. The drug product and active ingredient of custirsen sodium is a second-generation, 4-13-4 MOE-gapmer antisense oligonucleotide (ASO).

In some embodiments, custirsen may be added to 250 mL 0.9% sodium chloride (normal saline). In some embodiments, the dose may be administered using either a peripheral or central indwelling catheter intravenously as an infusion over 2 hours. Additionally, in some embodiments an infusion pump may be used.

General techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Horwood Books in the Biological Sciences. Series in Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modern Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol. 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.). These references in their entireties are hereby incorporated by reference into this application.

This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.

EXPERIMENTAL DETAILS Example 1 In Vivo Activity of Custirsen Against RPMI 8226 (Human Myeloma) Xenograft Model, Implanted Subcutaneously into Athymic Nude Mice

Summary

This study aimed to evaluate the effect of custirsen (OGX-11, TV-1011) against human myeloma model in nude mice. The cells were implanted subcutaneously into female SCID mice with 7×106 cells inoculum. On day 20, when the tumors reached 120-170 mm3, mice were sorted into two treatment groups (n=10): control group; and custirsen 40 mg/kg ip qd*5, then twk.

Tumors and body weights were measured weekly until termination of the study on day 71. Response to treatment was evaluated for tumor growth inhibition (TGI) and tumor growth delay (TGD).

Treatment with custirsen at a dose of 40 mg/kg was stopped after 7 injections due to toxicity. Nevertheless, as a monotherapy it significantly inhibited tumor growth by the end of the study.

Introduction

The objective of this study was to evaluate the effect of custirsen (OGX-11, Tv-1011) against human myeloma model in nude mice.

Materials and Methods

Materials

    • RPMI 8226 (Human Plasmacytoma, Myeloma B Cells) ATCC # CCL-155;
    • RPMI medium (Beit Haemek);
    • ECM Gel (Mtrigel), Sigma-Aldrich, Cat # E1270, 5 ml;
    • HBSS (Beit Haemek);
    • Custirsen (OGX-11, TV-1011) 20 mg/ml, K-46138;
    • Sodium chloride, TEVA.
      Animals

70 CB.17 SCID female mice, 4-6 weeks old, 16-20 grams, obtained from Harlan animal breeding center.

Cell Preparation

Harvested 14 flasks (T-175), passage 5, which were split 1:4. Sample from the cell suspension was taken for counting (0.3 ml in duplicates for CEDEX) before spun down. Cell viability was 85.6% and live cell concentration was 167×105 cells/ml. The pellet was resuspended in HBSS to a final volume of 8 ml.

Study Design

Tumors were implanted subcutaneously with RPMI-8226 cells into the right flank of the mouse on Day 0. Each animal received a s.c. injection 7×10 cells in 0.1 ml suspension. On day 20, mice were sorted by the optimal tumor volume (120-170 mm3) and were allocated into 5 groups of 10 mice. Mice were individually tagged and their tumor volume and body weight were monitored weekly during the study. Tumor size was measured by caliper and calculated using the formula:

π × ( width 2 ) 2 × length .

The treatment started on day 11 (0.2 ml per 20 grams v/w) and continued till day 52, after which the remaining mice were left for observation until day 71. Treatment regimen and doses are indicated in Table 1.

TABLE 1 Experimental design Drug and treatment Gr. N Agent mg/kg Route Schedule 1 10 Vehicle — ip ip qd * 5 + twk 2 10 Custirsen 40 ip ip qd * 5 + twk i.v. - intravenously, ip - intraperitoneally, twk - three times a week

Results

The treatment responses for Day 51 are summarized in Table 3 and presented in FIG. 1. Treatment with custirsen at a dose of 40 mg/kg was stopped after 7 injections (5 consecutive+2 on the next week). On day 34, one mouse in custirsen 40 mg/kg group died. On Day 51, animals started to exit the study due to tumor size. Treatment with custirsen as a monotherapy inhibited tumor growth compared to control group. Custirsen alone inhibited tumor growth by 46% (p<0.05). The study was terminated on day 71, when 1-3 mice left in each group. Survival data is shown in Table 3.

TABLE 2 Summary of the results (day 51) Δ mean Max BW Dose, tumor volume, % TGI No. of No. of (mean) No. of No. og Compound mg/kg Regimen (mean ± se) day 51 PR CR reduction TRD nTRD 1. Vehicle i.p. qd * 5, 1228 ± 142 0 0 −1.3% 0 0 twk day 34 2. Custirsen 40 ip qd * 5, 667 ± 87 46* 0 0 −4.7% 1 0 twk day 34 PR - partial response: tumor reduction below baseline measurement; CR - complete response: elimination of the tumor; TRD - treatment related death; NTRD - non treatment related death.

TABLE 3 Raw Data for Reduction in Myeloma Tumor Size with Custirsen Monotherapy % of Δ % of Δ Day 20, Day 27, Δ Δ base- vol- Day 34, Δ Δ base- vol- weight volume weight volume weight % line ume weight volume weight % line ume Vehicle 1 16.4 119 16.7 188 0.3 2.1 102.1 69.9 16.8 292 0.4 2.6 102.6 173.4 i.p. qd * 5, 2 20.0 125 21.1 208 1.1 5.4 105.4 83.7 20.2 274 0.2 0.7 100.7 149.4 twk 3 21.4 133 22.1 205 0.7 3.1 103.1 72.6 21.1 400 −0.3 −1.5 98.5 267.4 4 22.7 137 22.0 209 −0.7 −2.9 97.1 72.0 21.1 332 −1.6 −6.8 93.2 195.4 5 16.9 139 16.7 258 −0.2 −1.2 98.8 118.7 16.6 478 −0.3 −1.6 98.4 339.3 6 21.2 144 21.1 215 −0.1 −0.6 99.4 71.1 20.4 294 −0.8 −4.0 96.0 149.4 7 21.6 152 21.9 203 0.3 1.4 101.4 51.6 21.5 275 0.0 −0.1 99.9 122.8 8 21.1 159 21.4 210 0.3 1.6 101.6 51.2 20.7 351 −0.3 −1.5 98.5 192.6 9 19.1 162 19.5 218 0.5 2.5 102.5 56.8 19.0 359 −0.1 −0.4 99.6 197.7 10 20.8 163 20.4 246 −0.4 −2.0 98.0 83.7 20.6 446 −0.1 −0.7 99.3 282.9 Mean 20.1 143.1 20.3 216.2 0.2 0.9 100.9 73.1 19.8 350.1 −0.3 −1.3 98.7 207 n 10 10 10 10 10 10 10 10 10 10 10 10 10 10 SD 2.1 15.5 2.0 20.7 0.5 2.6 2.6 19.8 1.8 71.9 0.6 2.6 2.6 68.5 SE 0.7 4.9 0.6 6.5 0.2 0.8 0.8 6.3 0.6 22.7 0.2 0.8 0.8 21.7 Curtirsen40 1 16.1 119 18.2 96 2.1 13.2 113.2 −23.1 13.5 98 −2.5 −15.7 84.3 −20.6 ip qd * 5, 2 17.7 124 18.2 207 0.4 2.5 102.5 84.0 17.4 244 −0.3 −1.9 98.1 120.3 twk 3 17.1 125 18.0 171 0.8 4.8 104.8 46.2 17.1 223 −0.1 −0.4 99.6 97.9 4 20.6 139 20.8 249 0.2 1.1 101.1 110.4 19.5 257 −1.1 −5.5 94.5 117.8 5 19.7 141 19.7 222 0.1 0.3 100.3 81.2 19.1 305 −0.5 −2.7 97.3 163.9 6 18.6 145 18.4 246 −0.3 −1.3 98.7 100.3 18.0 336 −0.6 −3.5 96.5 190.8 7 18.4 151 18.9 319 0.4 2.4 102.4 168.8 18.2 371 −0.2 −1.1 98.9 219.9 8 20.0 155 20.3 193 0.3 1.7 101.7 38.8 19.0 220 −0.9 −4.7 95.3 65.4 9 18.4 162 18.6 217 0.2 0.8 100.8 55.3 17.2 266 −1.2 −6.7 93.3 104.3 10 18.9 169 19.0 271 0.1 0.5 100.5 102.6 18.0 312 −0.9 −4.6 95.4 142.9 Mean 18.5 142.8 19.0 219.2 0.4 2.6 102.6 76.4 17.7 263.1 −0.8 −4.7 95.3 120.3 n 10 10 10 10 10 10 10 10 10 10 10 10 10 10 SD 1.4 16.8 1.0 60.3 0.7 4.1 4.1 51.3 1.7 76.1 0.7 4.4 4.4 67.4 SE 0.4 5.3 0.3 19.1 0.2 1.3 1.3 16.2 0.5 24.1 0.2 1.4 1.4 21.3 % of Δ % of Δ Day 41, Δ Δ base- vol- Day 45, Δ Δ base- vol- weight volume weight % line ume weight volume weight % line ume Vehicle 1 17.2 370 0.8 4.6 104.6 251.4 17.7 371 1.4 8.2 108.2 252.2 i.p. qd * 5, 2 20.8 554 0.8 3.8 103.8 429.6 21.2 835 1.1 5.7 105.7 710.8 twk 3 21.6 688 0.2 1.1 101.1 555.7 22.2 945 0.8 3.7 103.7 812.5 4 22.5 659 −0.2 −0.7 99.3 522.1 22.6 880 0.0 −0.2 99.8 742.9 5 17.3 816 0.4 2.6 102.6 677.2 17.8 1118 0.9 5.6 105.6 979.0 6 21.0 577 −0.2 −0.9 99.1 432.6 21.7 811 0.4 2.1 102.1 666.8 7 22.2 402 0.6 2.9 102.9 250.2 22.9 475 1.3 6.1 106.1 323.2 8 21.3 505 0.2 1.0 101.0 346.5 21.8 795 0.7 3.5 103.5 636.2 9 19.4 735 0.4 2.0 102.0 573.1 19.9 844 0.8 4.3 104.3 682.6 10 21.2 977 0.4 2.0 102.0 814.1 22.7 1341 1.9 9.3 109.3 1178.6 Mean 20.4 628.3 0.3 1.8 101.8 485 21.0 841.6 0.9 4.8 104.8 698 n 10 10 10 10 10 10 10 10 10 10 10 10 SD 1.9 186.8 0.3 1.8 1.8 180.8 1.9 278.4 0.5 2.8 2.8 272.7 SE 0.6 59.1 0.1 0.6 0.6 57.2 0.6 88.0 0.2 0.9 0.9 86.2 Curtirsen40 1 ip qd*5, 2 18.8 410 1.1 6.0 106.0 286.2 19.2 511 1.4 8.1 108.1 388.0 twk 3 17.9 295 0.8 4.4 104.4 170.4 18.8 272 1.7 9.8 109.8 147.2 4 20.9 322 0.3 1.6 101.6 183.5 21.9 579 1.3 6.1 106.1 440.5 5 19.8 454 0.1 0.4 100.4 313.0 20.5 587 0.8 4.1 104.1 446.1 6 18.7 474 0.1 0.3 100.3 328.4 19.1 584 0.5 2.7 102.7 439.0 7 19.5 560 1.1 5.9 105.9 409.6 20.6 826 2.1 11.4 111.4 675.2 8 19.9 267 −0.1 −0.5 99.5 112.3 21.1 467 1.1 5.6 105.6 313.0 9 17.6 320 −0.8 −4.2 95.8 157.8 18.7 428 0.3 1.5 101.5 266.0 10 18.9 457 0.0 0.1 100.1 288.2 19.1 490 0.2 1.3 101.3 321.7 Mean 19.1 395.4 0.3 1.5 101.5 249.9 19.9 527.3 1.0 5.6 105.6 381.9 n 9 9 9 9 9 9 9 9 9 9 9 9 SD 1.0 99.0 0.6 3.3 3.3 97.8 1.1 149.6 0.6 3.6 3.6 147.4 SE 0.3 33.0 0.2 1.1 1.1 32.6 0.4 49.9 0.2 1.2 1.2 49.1 % of Δ % of Δ Day 48, Δ Δ base- vol- Day 51, Δ Δ base- vol- weight volume weight % line ume weight volume weight % line ume Vehicle 1 16.6 510 0.2 1.2 101.2 391.5 16.6 538 0.2 1.5 101.5 419.2 i.p. qd * 5, 2 20.8 1000 0.7 3.5 103.5 875.0 21.5 1330 1.4 7.1 107.1 1205.0 twk 3 22.0 1111 0.6 3.0 103.0 978.8 22.0 1487 0.6 2.9 102.9 1354.7 4 22.5 1140 −0.1 −0.5 99.5 1003.3 22.8 1408 0.2 0.8 100.8 1270.6 5 17.4 1409 0.6 3.4 103.4 1269.6 18.3 2054 1.4 8.2 108.2 1915.0 6 21.1 1002 −0.1 −0.7 99.3 857.5 21.4 1241 0.2 0.8 100.8 1096.6 7 22.5 720 1.0 4.5 104.5 567.9 22.6 794 1.0 4.8 104.8 642.1 8 21.5 986 0.4 2.0 102.0 827.1 21.7 1447 0.7 3.1 103.1 1289.0 9 20.1 1125 1.0 5.4 105.4 963.5 20.1 1482 1.0 5.5 105.5 1320.2 10 22.5 1388 1.7 8.4 108.4 1225.2 23.3 1934 2.6 12.4 112.4 1771.2 Mean 20.7 1039.0 0.6 3.0 103.0 896 21.0 1371.4 0.9 4.7 104.7 1228 n 10 10 10 10 10 10 10 10 10 10 10 10 SD 2.1 272.6 0.6 2.7 2.7 266.6 2.1 454.9 0.7 3.7 3.7 448.8 SE 0.7 86.2 0.2 0.9 0.9 84.3 0.7 143.9 0.2 1.2 1.2 141.9 Curtirsen40 1 ip qd * 5, 2 18.73 495 1.0 5.6 105.6 371.9 18.40 687 0.7 3.8 103.8 563.6 twk 3 18.93 354 1.8 10.6 110.6 229.1 18.79 392 1.7 9.8 109.8 267.5 4 21.36 689 0.8 3.7 103.7 550.6 21.71 817 1.1 5.4 105.4 678.0 5 20.43 763 0.8 3.8 103.8 621.8 20.17 923 0.5 2.5 102.5 781.6 6 19.03 717 0.4 2.1 102.1 571.9 19.13 1031 0.5 2.7 102.7 885.6 7 20.83 1076 2.4 13.0 113.0 925.7 21.05 1324 2.6 14.2 114.2 1173.4 8 20.79 483 0.8 4.2 104.2 329.0 20.78 603 0.8 4.2 104.2 448.7 9 18.98 593 0.6 3.2 103.2 431.2 18.47 734 0.1 0.4 100.4 571.8 10 19.13 671 0.2 1.2 101.2 502.7 19.87 804 1.0 5.1 105.1 635.5 Mean 19.8 649.2 1.0 5.3 105.3 503.8 19.8 812.8 1.0 5.3 105.3 667.3 n 9 9 9 9 9 9 9 9 9 9 9 9 SD 1.0 207.3 0.7 3.9 3.9 202.3 1.2 265.5 0.8 4.2 4.2 261.1 SE 0.3 69.1 0.2 1.3 1.3 67.4 0.4 88.5 0.3 1.4 1.4 87.0 % of Δ % of Δ Day 58 Δ Δ base- vol- Day 63 Δ Δ base- vol- weight volume weight % line ume weight volume weight % line ume Vehicle 1 17.5 830 1.1 6.8 106.8 711.8 17.3 1255 0.9 5.8 105.8 1136.3 i.p. qd * 5, 2 22.4 1934 2.4 11.8 111.8 1809.7 twk 3 23.2 2416 1.8 8.2 108.2 2283.1 4 23.8 3067 1.2 5.3 105.3 2929.9 5 6 22.4 1614 1.2 5.7 105.7 1469.9 7 23.2 856 1.7 7.7 107.7 704.4 22.7 1007 1.1 5.3 105.3 855.2 8 22.9 2006 1.8 8.6 108.6 1847.0 9 20.8 2331 1.8 9.2 109.2 2169.0 10 Mean 22.0 1881.7 1.6 7.9 107.9 1741 20.0 1130.9 1.0 5.5 105.5 996 n 8 8 8 8 8 8 2 2 2 2 2 2 SD 2.0 768.9 0.4 2.1 2.1 766.6 3.8 175.2 0.1 0.4 0.4 198.8 SE 0.7 271.8 0.1 0.7 0.7 271.0 2.7 123.9 0.1 0.3 0.3 140.5 Curtirsen40 1 ip qd * 5, 2 18.72 797 1.0 5.6 105.6 673.0 18.57 1127 0.8 4.7 104.7 1003.4 twk 3 18.84 560 1.7 10.0 110.0 435.6 19.25 848 2.1 12.4 112.4 723.2 4 22.31 1319 1.7 8.4 106.4 1180.5 22.39 2000 1.8 8.7 108.7 1861.0 5 20.77 1418 1.1 5.5 105.5 1277.2 21.04 2185 1.4 6.9 106.9 2043.7 6 19.53 1693 0.9 4.8 104.8 1547.4 7 21.42 1970 3.0 16.2 116.2 1819.3 8 21.45 1060 1.5 7.5 107.5 905.2 22.19 1918 2.2 11.2 111.2 1763.0 9 19.51 1218 1.1 6.0 106.0 1056.5 19.81 1519 1.4 7.7 107.7 1357.1 10 20.43 1475 1.5 8.1 108.1 1306.4 20.11 2426 1.2 6.4 106.4 2257.1 Mean 20.3 1278.9 1.5 8.0 108.0 1133.5 20.5 1717.4 1.6 8.3 108.3 1572.6 n 9 9 9 9 9 9 7 7 7 1 7 7 SD 1.3 434.3 0.6 3.5 3.5 426.0 1.5 575.1 0.5 2.7 2.7 563.0 SE 0.4 144.8 0.2 1.2 1.2 142.0 0.5 217.4 0.2 1.0 1.0 212.8

Example 2 In Vivo Activity of Custirsen (TV-1011) Against RPMI 8226 (Human Myeloma) Xenograft Model, Implanted Subcutaneously into Athymic Nude Mice

A previous in-house study demonstrated that custirsen had an inhibitory effect on tumor growth, but also showed unacceptable toxicity at a high dose.

In this study custirsen is administered using a different dose and regimen in order to avoid toxicity.

Materials and Methods

Test Articles

    • RPMI 8226 (Human Plasmacytoma, Myeloma B Cells) ATCC # CCL-155;
    • ECM Gel (Matrigel), Sigma-Aldrich, Cat # E1270, 5 ml;
    • RPMI (Beit Haemek);
    • Custirsen (TV-1011) 20 mg/ml, K-46138;
    • Sodium chloride, TEVA.
      Test Animals

120 CB.17 SCID female mice, 4-6 weeks old, 16-20 grams, obtained from Harlan animal breeding center.

Experimental Procedures

Cells Preparation

Cells (originated from ATCC) were cultured on RPMI medium. Cell suspension was centrifuged and resuspended in 50% Matrigel/HBSS to a final concentration of 7×107 cells/ml. The suspension was implanted s.c. in the right flank of the anesthetized mouse at a volume of 100 μl.

Compounds Preparation

11.2 ml of the stock solution of custirsen (TV-1011 20 mg/ml) were added to 44.8 ml saline to receive 4 mg/ml. 28.5 ml of 4 mg/ml were added to 9.5 saline to receive 3 mg/ml.

Experimental Design

Mice were implanted subcutaneously, with 7×10 RPMI 8226 cells/mouse (in 50% Martigel/HBSS) on Day 0. On day 21, mice were sorted by the optimal average tumor volume (˜130 mm3) and were allocated into 2 groups of 10 mice each.

Gr. N Agent Route Dose & schedule 1 10 Vehicle ip qd * 5, then biwk 2 10 Custirsen ip 30 qd * 5, 40 biwk “qd * 5” means daily dosing for 5 days; “biwk” means twice per week; “twk” means three times per week.

The treatment started on day 21 post implant, 0.2 ml per 20 grams v/w.

Statistical Analysis

Tumor volume was calculated as follows:

π × ( width 2 ) 2 × length .
The analysis of weight gain and tumor volume progression was made using one-way ANOVA followed by Tukey post-hoc comparisons.
Results

The treatment responses for Day 62 are summarized in FIG. 2 and Table 5.

Treatment with custirsen inhibited tumor growth compared to control group (Table 3). Custirsen alone inhibited tumor growth by 67% (p<0.001).

TABLE 4 Summary of the results (day 62) Maintenance Loading Dose, mg/ Total Δ mean Max BW Dose, mg/ kg/week dose, tumor volume, No. of No. of (mean) No. of No. og Compound Regimen kg/week *5 w mg/kg (mean ± se) % TGI PR CR reduction TRD nTRD Vehicle i.p. qd * 5, 1746 ± 218 0 0 −1.7% 0 0 then biwk day 28 Custirsen i.p. qd * 5, 150 80 * 5 550  574 ± 118 67*** 1 0 −0.5% 0 0 then biwk day 28 *p < 0.05, **p < 0.01, ***p < 0.001 (one-way Anova, Tukey post-hoc test)

Conclusions
    • Custirsen 30 mg/kg qd×5 then 40 mg/kg biwk—alone was very efficacious; this regimen was not toxic;
    • The effect of custirsen on tumor volume was statistically significant. See Table 4.

TABLE 5 Raw Data for Custirsen Monotherapy for Treatment of Myeloma % of % of Day 21 Day 28, Δ Δ base- Day 33, Δ Δ base- weight volume weight volume weight % line weight volume weight % line Vehicle 1 17.8 100 17.0 129 −0.8 −4.3 95.7 17.0 185 −0.8 −4.6 95.4 i.p. qd * 5, 2 19.2 113 19.5 150 0.3 1.7 101.7 20.6 253 1.4 7.4 107.4 then 3 21.1 116 21.6 244 0.4 2.1 102.1 21.1 270 0.0 −0.2 99.8 biwk 4 18.7 119 18.3 209 −0.4 −2.4 97.6 19.1 189 0.3 1.7 101.7 5 18.1 124 17.0 199 −1.1 −6.1 93.9 17.4 274 −0.6 −3.8 96.4 6 21.5 126 20.7 260 −0.8 −3.7 96.3 20.4 357 −1.1 −5.1 94.9 7 20.3 132 20.1 183 −0.2 −0.9 99.1 20.0 171 −0.2 −1.2 98.8 8 18.7 141 18.8 224 0.1 0.5 100.5 18.8 279 0.1 0.4 100.4 9 19.1 154 19.1 277 0.0 0.1 100.1 18.9 334 −0.2 −1.2 96.8 10 21.6 157 21.0 215 −0.8 −3.6 96.4 20.5 176 −1.3 −5.9 94.1 Mean 19.6 128.5 19.3 214.1 −0.3 −1.7 96.3 19.4 246.9 −0.3 −1.2 98.8 n 10 10 10 10 10 10 10 10 10 10 10 10 SD 1.5 18.2 1.6 45.9 0.5 2.8 2.6 1.4 68.9 0.8 3.9 3.9 SE 0.5 5.7 0.5 14.5 0.2 0.9 0.9 0.4 21.8 0.2 1.2 1.2 Curtirsen 1 21.4 107 21.0 78 −0.4 −2.0 98.0 20.9 132 −0.5 −2.2 97.8 30 mg/kg 2 17.7 113 16.5 127 0.8 4.4 104.4 19.2 131 1.5 8.3 108.3 qd * 5, 3 20.5 116 21.3 114 0.8 4.0 104.0 22.1 120 1.7 8.1 106.1 40 mg/kg 4 15.9 119 16.3 149 0.4 2.6 102.6 15.2 116 −0.6 −4.1 95.9 biwk 5 19.6 123 16.7 180 −0.9 −4.8 95.2 18.4 167 −1.2 −6.0 94.0 6 20.3 128 19.6 204 −0.6 −3.1 96.9 20.5 157 0.3 1.3 101.3 7 17.9 131 16.9 159 −1.0 −5.6 94.4 17.6 100 −0.3 −1.7 96.3 8 16.6 138 17.1 175 0.5 3.0 103.0 17.5 154 0.9 5.5 105.5 9 20.1 147 19.9 193 −0.3 −1.3 98.7 20.1 206 0.0 −0.1 99.9 10 17.8 172 17.5 204 −0.3 −1.7 98.3 19.1 186 1.3 7.3 107.3 Mean 18.8 129.3 18.7 158.1 −0.1 −0.5 99.5 19.1 147.0 0.3 1.6 101.6 n 10 10 10 10 10 10 10 10 10 10 10 10 SD 1.8 19.2 1.7 41.7 0.7 3.7 3.7 2.0 33.3 1.0 5.3 5.3 SE 0.6 6.1 0.6 13.2 0.2 1.2 1.2 0.6 10.5 0.3 1.7 1.7 % of % of Day 41, Δ Δ base- Day 48, Δ Δ base- weight volume weight % line weight volume weight % line Vehicle 1 16.9 235 −0.8 −4.6 95.4 16.8 341 −1.0 −5.5 94.5 i.p. qd * 5, 2 20.0 359 0.8 4.1 104.1 21.7 514 2.6 13.4 113.4 then 3 21.1 368 0.0 0.1 100.1 21.6 460 0.5 2.2 102.2 biwk 4 18.9 285 0.2 0.9 100.9 19.5 674 0.7 4.0 104.0 5 18.1 336 0.1 0.3 100.3 18.2 384 0.1 0.6 100.6 6 21.6 509 0.1 0.3 100.3 22.3 813 0.8 3.6 103.6 7 20.3 481 0.1 0.3 100.3 20.5 726 0.3 1.3 101.3 8 20.2 449 1.5 7.8 107.8 19.8 755 0.8 4.5 104.5 9 19.4 607 0.3 1.5 101.5 20.1 1104 1.1 5.5 105.5 10 20.6 264 −1.2 −5.6 94.4 21.2 410 −0.6 −2.9 97.1 Mean 19.7 389.5 0.1 0.5 100.5 20.1 618.0 0.5 2.7 102.7 n 10 10 10 10 10 10 10 10 10 10 SD 1.4 119.4 0.7 3.8 3.8 1.7 240.0 1.0 5.1 5.1 SE 0.4 37.7 0.2 1.2 1.2 0.5 75.9 0.3 1.6 1.6 Curtirsen 1 21.7 76 0.3 1.4 101.4 23.2 101 1.8 8.5 108.5 30 mg/kg 2 20.0 144 2.3 12.9 112.9 20.6 360 3.0 16.7 116.7 qd * 5, 3 22.8 140 2.3 11.2 111.2 23.1 268 2.6 12.9 112.9 40 mg/kg 4 17.2 139 1.3 8.4 108.4 19.1 267 3.3 20.7 120.7 biwk 5 20.2 336 0.6 2.9 102.9 21.6 556 2.0 10.1 110.1 6 20.7 249 0.5 2.3 102.3 21.6 581 1.5 7.6 107.6 7 18.9 192 1.1 5.9 105.9 20.5 211 2.6 14.4 114.4 8 18.7 185 2.0 12.3 112.3 20.5 257 3.9 23.3 123.3 9 21.5 223 1.3 6.7 106.7 23.3 451 3.2 15.7 115.7 10 18.5 200 0.7 3.9 103.9 19.3 392 1.5 8.4 108.4 Mean 20.0 184.3 1.2 6.8 106.8 21.3 344.4 2.5 13.8 113.8 n 10 10 10 10 10 10 10 10 10 10 SD 1.7 72.4 0.8 4.3 4.3 1.6 153.2 0.8 5.4 5.4 SE 0.5 22.9 0.2 1.3 1.3 0.5 48.4 0.3 1.7 1.7 % of % of Δ Day 55 Δ Δ base- Day 62 Δ Δ base- vol- weight volume weight % line weight volume weight % line ume Vehicle 1 17.4 540 −0.4 −2.3 97.7 17.8 1005 0.0 0.3 100.3 905.5 i.p. qd * 5, 2 21.8 1417 2.6 13.7 113.7 22.9 2026 3.7 19.3 119.3 1913.4 then 3 22.0 900 0.8 4.0 104.0 22.2 1554 1.1 5.0 105.0 1437.1 biwk 4 21.4 1242 2.6 14.1 114.1 21.1 2256 2.4 12.7 112.7 2137.4 5 19.6 544 1.6 8.6 108.6 19.0 953 0.9 4.8 104.8 829.0 6 23.0 1495 1.5 6.9 106.9 23.7 2418 2.2 10.0 110.0 2289.3 7 22.0 1100 1.7 8.4 108.4 22.1 2252 1.8 8.9 108.9 2119.3 8 21.1 1260 2.4 12.7 112.7 22.2 2291 3.5 18.8 118.8 2150.2 9 20.9 1667 1.8 9.3 109.3 22.4 2945 3.3 17.1 117.1 2790.8 10 22.3 599 0.5 2.2 102.2 23.0 1040 1.2 5.4 105.4 882.7 Mean 21.1 1076.5 1.5 7.8 107.8 21.6 1874.0 2.0 10.2 110.2 1745.6 n 10 10 10 10 10 10 10 10 10 10 10 SD 1.6 412.5 1.0 5.3 5.3 1.9 693.6 1.2 6.6 6.6 687.9 SE 0.5 130.4 0.3 1.7 1.7 0.6 219.3 0.4 2.1 2.1 217.5 Curtirsen 1 22.1 106 0.7 3.3 103.3 22.7 92 1.3 5.9 105.9 −14.3 30 mg/kg 2 20.7 638 3.0 16.7 116.7 21.5 955 3.9 21.8 121.8 842.5 qd * 5, 3 22.4 463 2.0 9.7 109.7 22.8 891 2.3 11.4 111.4 775.4 40 mg/kg 4 19.5 399 3.6 22.9 122.9 18.8 568 3.0 18.7 118.7 448.8 biwk 5 20.2 767 0.6 3.1 103.1 20.8 1324 1.2 6.2 106.2 1200.9 6 21.1 663 0.8 4.0 104.0 21.7 804 1.4 7.1 107.1 676.2 7 19.0 257 1.1 6.1 106.1 19.1 379 1.2 6.8 105.8 247.2 8 19.0 246 2.3 14.0 114.0 19.8 273 3.2 19.0 119.0 135.4 9 21.8 638 1.7 8.4 108.4 22.6 1001 2.5 12.4 112.4 853.6 10 18.4 588 0.7 3.7 103.7 18.9 742 1.1 6.3 106.3 570.4 Mean 20.4 476.6 1.7 9.2 109.2 20.9 702.9 2.1 11.5 111.5 573.6 n 10 10 10 10 10 10 10 10 10 10 10 SD 1.4 218.0 1.1 6.7 6.7 1.6 375.1 1.0 6.2 6.2 373.4 SE 0.5 68.9 0.3 2.1 2.1 0.5 118.6 0.3 1.9 1.9 118.1

Example 3 In Vivo Activity of Custirsen (OGX-11) Against PC-3 (Human Prostate Carcinoma) Xenograft Model, Implanted Subcutaneously into Athymic Nude Mice

The cells were implanted subcutaneously into female immunodeficient nude mice. On day 14, when the tumors reached 90-135=3, mice were sorted into treatment groups (n=10): 1. Control group was treated with saline i.p. qd*7+twk; 2. Custirsen treatment (25 mg/kg ip qd*5+twk).

Tumors and body weights were measured once a week until termination of the study on day 58 included. Response to treatment was evaluated for tumor growth inhibition (TGI) and expressed as the difference between the mean tumor volumes of treated and control mice.

Materials and Methods

a. Materials

    • PC-3 (Human Prostate Adenocarcinoma), ATCC, CAL-1435™
    • RPMI medium 1640+L-Glutamine (Beit Haemek)
    • Custirsen (OGX) 20 mg/ml, K-46138;
    • The custirsen solution was prepared once weekly and stored at 4° C. 4.0 ml of the stock solution of custirsen (20 mg/ml) were added to 60 ml saline. (1:16 dilution)
    • Saline (TEVA).
      b. Animals

Mutant Athymic Nude female mice, 4-6 weeks old, 16-20 grams, obtained from Harlan animal breeding center.

c. Cell Preparation

Harvested 20 flasks (T-175), passage 7, which were split 1:4. Cells were cultured (P-3, originated from ATCC). A sample from the cell suspension was taken for counting (0.3 ml in duplicates for CEDEX) before spun down. Cell viability was 99.4% and live cell concentration was 49.2×10 cells/ml and pellet was re-suspended with HESS to a final concentration of 3×107/ml (3×106 cells/0.1 ml/mouse).

d. Study Design

Tumors were implanted subcutaneously with PC-3 cells in the right dorsal of the mouse on Day 0. Each mouse was injected with 0.1 ml cell suspension from a concentration of 3×107 cells/ml. On day 14, mice were sorted by the optimal tumor volume (90-135 mm3) and were allocated into groups of 10 mice (Table 6). Mice were individually tagged and their tumor volume and body weight were monitored weekly during the study. Tumor size was measured by caliper and calculated using the formula:

π × ( width 2 ) 2 × length .

The treatment started on day 15 (0.2 ml per 20 grams v/w) and continued till day 58. Treatment regimen and doses are indicated in Table 6.

Results

The treatment responses are summarized in Table 7 and presented in FIG. 3.

The custirsen (OGX) treatment at 25 mg/kg alone had a moderate effect by itself, 32% TGI (not significant) compare to the vehicle group. Additionally, the stand alone efficacy of custirsen at 25 mg/kg was significantly different than that of vehicle at 1 time point (4 weeks).

TABLE 6 Experimental design Drug and treatment Gr. N Agent mg/kg Route Schedule 1 10 Vehicle — ip qd * 5 + twk 2 10 Custrisen 25 ip qd * 5 + twk ip - intraperitoneal; qd - every day; twk - three times a week; qd * 5 - daily dosing for 5 days.

TABLE 7 Summary of the results (day 58) Antitumor Activity of Custirsen (OGX-11; TV-1011) against PC-3 Started 14 days post implant Ended 58 Days post implant Tumor Drugs Delta Mean Animals Dose Tumor Volume Delta % Dead/ Compount Route Regimen (mg/kg) (mm3 ± SEM) % T/C % TGI Body Wt. Total Saline i.p qd * 5 + twk — 569 ± 79.48 —  1.4 ± 1.29 0/10 OGX i.p qd * 5 + twk 25 mg/kg 385 ± 93.95 68 32 7.61 ± 2.08 0/10 *p < 0.05, **p < 0.01, ***p < 0.001 (one-way Anova, Tukey post-hoc test)

Conclusion

Although custirsen is not currently a therapeutic agent as a stand alone standard care, it demonstrated in this study a moderate effect of 32% TGI (not statistically significant) at a higher tested dose (than pervious studies) of 25 mg/kg. The effect of custirsen monotherapy was statistically significant at the week 4 time point, however.

TABLE 8 Raw Data. Tumor volumes and body weights Tumor Volume Day: 14 22 DELTA 29 DELTA 38 DELTA 43 DELTA 51 DELTA 58 DELTA Group 1 1 96 227 131 259 163 422 326 484 389 362 256 394 298 Vehicle 2 99 308 209 386 287 624 525 737 639 859 760 1057 958 Saline 3 102 198 96 333 231 393 291 478 376 518 416 612 510 qd * 5 + twk 4 106 175 69 289 182 412 305 444 338 537 431 636 529 5 107 189 81 435 327 536 429 623 516 738 631 770 662 6 113 172 59 258 144 408 294 419 305 388 275 513 400 7 116 271 156 425 309 567 451 742 626 763 648 1119 1003 8 119 235 117 317 199 415 296 482 364 457 338 476 357 9 120 214 94 430 310 459 339 571 451 513 393 767 647 10 126 246 120 382 256 628 502 737 611 705 580 446 321 Average 110 224 113 351 241 486 376 572 461 584 474 679 569 STD Dev 9.82 43.44 44.77 69.45 66.63 93.32 91.72 129.26 127.32 170.44 170.21 250.13 251.33 SEM 3.10 13.74 14.16 21.96 21.07 29.51 29.01 40.88 40.26 53.90 53.82 79.10 79.48 Group 2 1 98 129 32 147 50 124 27 98 0 0 −98 0 −98 Custirsen 2 98 109 11 134 36 200 102 302 204 278 180 344 246 qd * 5 + twk 3 103 177 74 221 118 372 269 401 298 433 330 526 423 25 mg/kg 4 105 179 74 261 156 519 413 452 346 612 507 128 23 5 110 213 102 246 136 278 168 192 82 135 24 807 697 6 113 258 145 356 244 625 512 708 596 717 605 895 782 7 114 223 109 285 171 366 252 498 384 599 485 698 584 8 118 204 587 236 119 321 203 473 355 377 259 259 142 9 122 204 82 323 202 409 287 475 354 570 448 558 437 10 124 200 75 240 116 444 319 481 356 596 472 740 615 Average 110 190 79 245 135 366 255 408 298 432 321 496 385 STD Dev 9.38 43.76 37.75 69.09 63.24 146.75 142.31 172.77 167.51 233.17 227.92 302.09 297.08 SEM 2.97 13.84 11.94 21.85 20.00 46.41 45.00 54.63 52.97 73.73 72.07 95.53 93.95 Body Weight Day: 14 22 Δ (%) 29 Δ (%) 38 Δ (%) 43 Δ (%) 51 Δ (%) 58 Δ (%) Group 1 1 23.75 23.91 0.68 23.62 −0.57 24.38 2.62 24.14 1.62 23.04 −3.00 23.08 −2.83 Vehicle 2 22.28 22.80 2.37 22.82 2.44 23.26 4.43 23.25 4.38 23.74 6.57 23.29 4.55 Saline 3 22.89 23.39 3.08 23.23 2.40 23.09 1.79 23.09 1.76 23.20 2.26 23.07 1.69 qd * 5 + twk 4 21.70 21.14 −2.56 21.79 0.43 22.17 2.17 22.44 3.41 22.86 5.35 22.56 3.97 5 24.41 24.93 2.09 25.20 3.23 24.44 0.09 23.95 −1.92 24.12 −1.20 23.33 −4.44 6 24.00 25.14 4.74 25.37 5.70 25.77 7.39 26.06 8.56 26.66 11.08 25.66 6.92 7 23.28 23.58 1.27 24.48 5.13 24.03 3.21 24.01 3.13 24.91 6.99 24.26 4.20 8 22.22 22.03 −0.86 23.06 3.79 23.33 5.01 23.56 6.03 23.04 3.70 23.22 4.51 9 25.60 24.94 −2.58 26.54 3.67 26.15 2.16 26.13 2.06 25.40 −0.77 24.55 −4.09 10 24.54 23.94 −2.43 25.28 3.02 24.57 0.15 24.78 1.01 25.28 3.03 24.43 −0.43 Average 23.45 23.58 0.58 24.14 2.93 24.12 2.90 24.14 3.00 24.23 3.40 23.75 1.40 STD Dev 1.23 1.30 2.59 1.46 1.91 1.22 2.23 1.21 2.88 1.28 4.31 0.94 4.08 SEM 0.39 0.41 0.82 0.46 0.60 0.39 0.71 0.38 0.91 0.41 1.36 0.30 1.29 Group 2 1 22.55 24.36 8.05 23.12 2.54 23.86 5.83 25.10 11.31 25.06 11.15 25.19 11.72 Custirsen 2 22.84 24.77 8.43 23.82 4.27 25.07 9.77 26.82 17.42 25.95 13.61 25.61 12.12 qd * 5 + twk 3 21.68 23.33 7.61 19.88 −8.31 23.16 6.81 24.75 14.15 23.36 7.74 23.50 8.39 25 mg/kg 4 23.27 23.78 2.23 19.96 −14.20 22.57 −2.97 24.98 7.35 22.85 −1.78 26.73 14.89 5 23.06 22.95 −0.47 23.59 2.28 25.65 11.23 26.26 13.87 26.86 16.47 22.28 −3.39 6 22.35 22.85 2.27 21.29 −4.72 22.14 −0.93 23.30 4.28 22.77 1.90 22.29 −0.25 7 24.33 26.74 9.92 25.50 4.83 25.93 6.59 26.92 10.65 26.31 8.14 26.55 9.12 8 23.49 27.32 16.30 25.41 8.17 26.52 12.91 28.16 19.87 27.91 18.83 27.31 16.28 9 21.68 24.75 14.17 23.07 6.43 22.88 5.54 23.38 7.87 23.95 10.50 22.83 5.33 10 20.35 21.37 4.99 21.22 4.25 21.44 5.35 21.79 7.06 20.84 2.40 20.74 1.91 Average 22.56 24.22 7.35 22.68 0.55 23.92 6.01 25.14 11.38 24.59 8.90 24.30 7.61 STD Dev 1.12 1.80 5.31 2.03 7.22 1.76 4.94 1.95 4.95 2.20 6.61 2.26 6.57 SEM 0.35 0.57 1.68 0.64 2.28 0.56 1.56 0.62 1.57 0.70 2.09 0.72 2.08

Secretary clusterin (sCLU)-2 is a stress-activated, cytoprotective chaperone that confers broad-spectrum cancer treatment resistance and its targeted inhibitor (TV-1011) is currently in Phase III trials for prostate cancer. TV-1011, also known as custirsen, which can be in the form of custirsen sodium, inhibits the production of clusterin, a protein that is associated with treatment resistance in a number of solid tumors and hematological cancer, including human myeloma (plasmacytoma, B cells) along with prostate, breast, non-small cell lung, ovarian, and bladder cancers. It has potential applicability as a therapeutic in a broad number of cancers at different stages and can potentially be used in combination with a variety of commonly used cancer treatments, including chemotherapy, radiation therapy, and hormone ablation therapy.

The present invention relates to the surprising discovery that custirsen is effective for cancer treatment as a monotherapy.

REFERENCES

  • 1. D'Addario et al., Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology.
  • 2. Fidias and Novello, Strategies for Prolonged Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28(34): 5116-5123.
  • 3. Jamal et al., Global Cancer statistics, 2011. CA Cancer J Clin; 2011, 61:69-90.
  • 4. Langer et al., The Evolving Role of Histology in the Management of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28(36):5311-5320.
  • 5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer, V.2.2010. National Comprehensive Cancer Network, Inc., Mar. 5, 2010.
  • 6. National Cancer Institute, General Information about Non-Small Cell Lung Cancer. http://www.cancer.gov/CANCERTOPICS/PDWTREATMENT/NON-SMALL-CELL-LUNG/PATIENT, accessed Feb. 24, 2011.

Claims

1. A method of treating myeloma in a subject afflicted with myeloma comprising administering to the subject an anti-clusterin oligonucleotide as a monotherapy to treat the myeloma.

2. The method of claim 1, wherein the anti-clusterin oligonucleotide is administered to the subject periodically.

3. The method of claim 1, wherein the anti-clusterin oligonucleotide comprises nucleotides in the sequence CAGCAGCAGAGTCTTCATCAT (SEQ ID NO: 1).

4. The method of claim 1, wherein the anti-clusterin oligonucleotide is modified to increase its stability in vivo.

5. The method of claim 4, wherein the anti-clusterin oligonucleotide comprises nucleotides in the sequence CAGCAGCAGAGTCTTCATCAT (SEQ ID NO: 1), has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4 and 19.

6. The method of claim 1, wherein the myeloma is unresectable, advanced or metastatic myeloma.

7. The method of claim 1, wherein the subject is a mammalian subject.

8. The method of claim 1, wherein the mammalian subject is a human subject.

9. The method of claim 1, wherein the anti-clusterin oligonucleotide is administered to the subject intravenously in an aqueous solution comprising sodium ions.

10. The method of claim 8, wherein the anti-clusterin oligonucleotide is administered to the subject as 3 separate loading doses within 5 to 9 day period at the beginning of treatment and then once weekly thereafter.

11. The method of claim 10, wherein the dose of the anti-clusterin oligonucleotides increases over each of the 3 loading doses.

12. The method of claim 10, wherein the first, second and third loading doses are 320, 480 and 640 mg, respectively.

13. The method of claim 8, wherein 640 mg of the anti-clusterin oligonucleotide is administered to the human subject.

Referenced Cited
U.S. Patent Documents
6900187 May 31, 2005 Gleave et al.
7285541 October 23, 2007 Gleave et al.
7368436 May 6, 2008 Gleave et al.
7534773 May 19, 2009 Gleave et al.
7569551 August 4, 2009 Gleave et al.
7592323 September 22, 2009 Gleave et al.
7732422 June 8, 2010 Gleave et al.
8173615 May 8, 2012 Gleave et al.
8361981 January 29, 2013 Gleave et al.
8536149 September 17, 2013 Gleave et al.
8710020 April 29, 2014 Gleave et al.
20080014198 January 17, 2008 Gleave et al.
20080119425 May 22, 2008 Gleave et al.
20110142827 June 16, 2011 Gleave et al.
20120282251 November 8, 2012 Tremblay et al.
20130017272 January 17, 2013 Duksin et al.
20130143944 June 6, 2013 Gleave et al.
20130310440 November 21, 2013 Duskin et al.
20140080895 March 20, 2014 Gleave et al.
20140088178 March 27, 2014 Gleave et al.
20140100261 April 10, 2014 Gleave et al.
Foreign Patent Documents
WO 00/49937 August 2000 WO
WO 03/072591 September 2003 WO
WO 2004/018675 March 2004 WO
WO 2005/094899 October 2005 WO
WO 2006/056054 June 2006 WO
WO 2012/123820 September 2012 WO
WO 2012/123823 September 2012 WO
WO 2012/156817 November 2012 WO
WO 2013/173757 November 2013 WO
WO 2014/159775 October 2014 WO
Other references
  • Jul. 10, 2014 International Search Report issued in connection with PCT International Patent Application No. PCT/US14/25092.
  • Jul. 10, 2014 Written Opinioin issued in connection with PCT International Patent Application No. PCT/US14/25092.
  • Niu et al., “Small Interfering RNA Targeted to Secretory Clusterin Blocks Tumor Crowtn, Motility, and Invasion in Breast Cancer.” Acta Biochim Biophy Sin (Shanghai) 44 (12): 991-998 (2012).
  • Dytfeld, D., MD, Phd., Proteomic Profiling of Multiple Myeloma Plasma Cells and Normal Plasma Cells Reveals Differential Expression of Clu1 and Basp1 Proteins, 53rd ASH Annual Meeting and Exposition, 2010, Retrieved on Feb. 4, 2016 from https://ash.confex.com/ash/2010/webprogram/Paper30449.html.
  • Rauhala, H. et al, CLU (clusterin), Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2009, Retrieved on Jan. 14, 2016 from http://atlasgeneticsoncology.org/Genes/GC—CLU.html.
Patent History
Patent number: 9359606
Type: Grant
Filed: Mar 12, 2014
Date of Patent: Jun 7, 2016
Patent Publication Number: 20140275215
Assignee: ONCOGENEX TECHNOLOGIES INC. (Vancouver)
Inventors: Shoshi Tessler (Zichron Ya'acov), Joel Kaye (Netanya), Tania Fine (Netanya), Rina Kashi (Alfai-Menashe)
Primary Examiner: Sean McGarry
Application Number: 14/207,471
Classifications
Current U.S. Class: 514/44
International Classification: A61K 31/70 (20060101); C07H 21/02 (20060101); C07H 21/04 (20060101); C12N 15/113 (20100101); A61K 31/711 (20060101); C12Q 1/68 (20060101);